EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) have revolutionised treatment of non-small cell lung cancer (NSCLC) in patients with EGFR mutations.